ICU Medical, Inc. (NASDAQ:ICUI) Receives $177.25 Consensus Target Price from Brokerages

Shares of ICU Medical, Inc. (NASDAQ:ICUI) have earned an average rating of “Moderate Buy” from the four brokerages that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $199.67.

Several equities research analysts have commented on the stock. Jefferies Financial Group raised shares of ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 price target on the stock in a research report on Wednesday, December 11th. KeyCorp raised their target price on shares of ICU Medical from $198.00 to $209.00 and gave the company an “overweight” rating in a research note on Wednesday, November 13th. Needham & Company LLC reissued a “hold” rating on shares of ICU Medical in a research report on Wednesday, November 13th. StockNews.com raised shares of ICU Medical from a “hold” rating to a “buy” rating in a report on Wednesday, November 20th. Finally, Raymond James lifted their price target on ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a report on Thursday, September 12th.

ICU Medical Stock Down 2.4 %

ICUI stock opened at $161.64 on Friday. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.29 and a quick ratio of 1.03. The stock has a market capitalization of $3.96 billion, a P/E ratio of -35.37 and a beta of 0.62. ICU Medical has a fifty-two week low of $86.80 and a fifty-two week high of $196.26. The business has a 50-day moving average of $171.12 and a 200-day moving average of $151.65.

Insider Buying and Selling at ICU Medical

In other ICU Medical news, Director David C. Greenberg sold 972 shares of the firm’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $158.11, for a total value of $153,682.92. Following the transaction, the director now directly owns 5,037 shares of the company’s stock, valued at $796,400.07. This trade represents a 16.18 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Vivek Jain sold 12,000 shares of the company’s stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $171.84, for a total transaction of $2,062,080.00. Following the sale, the chief executive officer now directly owns 104,593 shares of the company’s stock, valued at approximately $17,973,261.12. This trade represents a 10.29 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 40,364 shares of company stock valued at $6,869,878 in the last quarter. Company insiders own 6.70% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Hexagon Capital Partners LLC raised its stake in ICU Medical by 162.7% during the third quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier’s stock worth $36,000 after acquiring an additional 122 shares in the last quarter. Allworth Financial LP grew its holdings in shares of ICU Medical by 100.0% during the 3rd quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 100 shares during the last quarter. Innealta Capital LLC acquired a new position in ICU Medical during the 2nd quarter worth approximately $32,000. Venturi Wealth Management LLC lifted its stake in ICU Medical by 1,510.0% in the 3rd quarter. Venturi Wealth Management LLC now owns 322 shares of the medical instruments supplier’s stock valued at $59,000 after purchasing an additional 302 shares during the last quarter. Finally, Point72 Hong Kong Ltd acquired a new stake in ICU Medical in the third quarter valued at approximately $72,000. 96.10% of the stock is currently owned by institutional investors and hedge funds.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.